Dutch company Galapagos, situated in Leiden, published the results of their most recent phase 3 clinical study. The drug, filgotinib, is a highly selective JAK1 inhibitor which can be used to treat rheumatoid arthirits, Crohn’s disease, ulcerative colitive. The effect on other diseases is still being researched. The drug was tested in more than 3000 patients and “has shown favorable results in terms of onset of action, efficacy, safety, and tolerability.”
The company is publicly listed and the stock value went up by about 20% on the day of publishing. The results have yet to be peer-reviewed, but they show a lot of promise!